Jardiance · DIN 02443945 · 25 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Jardiance · DIN 02443945
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2016-05-31
Health Canada: Marketed since 2015-08-11 · brand JARDIANCE · ATC A10BK03 EMPAGLIFLOZIN · form Tablet · route Oral · ingredients EMPAGLIFLOZIN 25 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Jardiance: Formulary list price $2.89 per unit (the source does not state the unit; exact figure $2.8868). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443945)
Source record
DIN 02443945: Jardiance
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002058; group id 743; item number 1816; lccId None; manufacturer id BOE
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $2.8868; ministry $2.8868
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443945
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92872
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:
- history of MI
- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)
- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection
- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease
- history of ischemic or hemorrhagic stroke
- occlusive peripheral artery disease.
Shortage status: not checked (no credentials)